Spine BioPharma's $13M investment to support degenerative disc disease treatment

Spine

Spine BioPharma received a $14 million series B round of funding that will support its injectable treatment for degenerative disc disease.

The funding will support development for the company's SB-1 Remedisc treatment, according to a March 28 news release. It is a seven-amino acid chain peptide and designed to decrease inflammation and maintain the structural integrity of the disc.

The funding was led by Viscogliosi Bros. Existing investors include Cercano Management and Pacira Biosciences.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Whitepapers